where T is the CC population, Csc is the CSC population, I is the ICC population, Ttot is the total density of cells given by the sum of the three populations, and , and are the proliferation/degradation rates of CCs, CSCs and ICCs, respectively (given below in Eq. (7)).
Tumor microenvironment components
In our model, we account for interactions among cancer cells, cancer stem cells, cells of the immune system and the tumor vasculature, which are described below.
Cancer cells
The population dynamics of non-stem cancer cells (CCs), stem-cell-like cancer cells (CSCs, which are resistant to drugs, hypoxia and immune system) and induced cancer cells (ICCs, CCs that are induced by chemotherapy to acquire a more stem-like phenotype) are described by (8) (9) (10) : ICCs as a function of oxygen. For the coefficients of the proliferation rates of CSCs and ICCs, i.e., αcsc and αI, respectively, we assume that for normal oxygen levels they are equal to one so that all cancer cell types have the same proliferation as that of CCs. In hypoxic conditions, however, the proliferation of cancer cells with a stem-like phenotype increases. Thus, we assume that their proliferation increases inversely proportional to the oxygen concentration so that as oxygen concentration approaches zero, the proliferation rates are twice as much as the rate in normal oxygen (11) . For the parameters ccsc, Dcsc, cI, and DI that describe the killing potential of immune cells on CSCs and ICCs, we assume that they are more resistant in interactions with immune cells.
According to experimental data (12) , the cytotoxicity of CD8 + T-cells against CSCs is taken to be 7-fold lower than that of CCs. As a result, the parameters that describe the killing of CSCs by immune cells are assumed to be the same as for the CCs but multiplied by a factor of 0.14. The rates of transfer of cancer cells from a type i to a type j are described by pij and their values were determined in (10) . Additionally, the parameter λΜ1 denotes the tumoricidal effect of M1-like TAMs in cancer cells according to Ref. (13) .
The dependence of cancer cell proliferation on the local oxygen concentration, G, is assumed to follow Michaelis-Menten kinetics and has the form (14, 15):
where k1 and k2 are growth rate parameters and cox is the oxygen concentration.
The creation/degradation of the solid phase, , and is expressed as (8): T  CT sc  IT  TC  TI  M   c  Csc  sc  sc  TC  IC  CT  CI  sc   c  I  I  I  I  TI  CI sc  IT 
Immune cells 
where Cd4 is the population of CD4 + T-cells and Treg is the population of the Treg cells.
Furthermore, fNK, mT8 and mreg are death rates of NK cells, CD8 + T-cells and Treg cells respectively, gNK, jT8 and greg are recruitment rates of immune cells, pim and q are inactivation rates of immune cells by CCs, σnk and σT8 are constant sources of NK and CD8 + T-cells respectively, rN is the rate at which tumor-specific CD8 + T-cells are stimulated to be produced as a result of tumor cells killed by NK cells and λreg is the inhibition term of NK cells and CD8 + T-cells from Treg cells. Under anoxic conditions we used the lowest value for the activity of NK cells and CD8 + Tcells reported in de Pillis et al. (9) , which increased linearly to the highest value for normal oxygen conditions. The values of fNK and mT8 are modified to depend on oxygen levels. According to experimental data (18), a 40 times decrease in oxygen concentration (from 20% to 0.5%) doubled the apoptotic rate of immune cells. Additionally sCD4 is the source of CD4 + T-cells, μCd4 is the natural death rate of CD4 + T-cells, reCd4 is the growth rate of CD4 + T-cells and Cd4,max is the maximum CD4 + T-cells population (19, 20) . rCd4 is the stimulation rate of CD8 + T-cells by CD4 + T-cells as mentioned previously (21) (22) (23) . The source term of CD4 + T-cells sCD4 will depend on oxygen concentration, as according to previous studies under hypoxic conditions it decreased 8 times (24) . Furthermore, a decrease of M2-like TAMs resulted in higher numbers of CD8 + T-cells and NK cells, while CD4 + T-cells were not affected according to experimental data (25) and these observations are described by the parameter λΜ2. The equations for populations of cells are rendered dimensionless by dividing the number of cells per finite element node by the initial number of cancer cells, T0=5×10 2 cells. The initial population of cancer cells was taken to be: 98% CCs, 1% CSCs and 1% ICCs (26) .
The parameter D denotes the fractional cell kill of tumor cells by CD8 + T-cells and given by equation (9, 27) :
where dim is the saturation level of fractional tumor cell kill by CD8 + T-cells, s is steepness coefficient of the tumor-CD8 + T-cells competition term and λim the exponent of fractional cell kill by CD8 + T-cells.
Immunotherapy with anti-PD-1 is modeled as an increase in the source term of CD8 + T-cells, σT8
and with anti-CTLA-4 as an increase of death rate of Treg cells, mreg.
Tumor Associated Macrophages (TAMs)
We account for two different types of TAMs, M1-like and M2-like:
gM1 and gM2 are the production rates of M1-like and M2-like TAMs, which depend on oxygen levels according to previous studies (25, 28, 29) showing that a decrease in hypoxia skewing TAM polarization away from the M2-to M1-like phenotype. According to previous studies TAMs are associated with VEGF expression (25, 30, 31) . Specifically, VEGF-A overexpression correlated with higher numbers of M2-like TAMs (rCvegf,M2).
Biphasic formulation of the tumor's mechanical behavior
The mass balance equation for the fluid phase is (5, 7) :
where Φ f is the volume fraction of the fluid phase and v f is the corresponding velocity. The sum of fluid and solid phase is equal to unity. Fluid velocity v f is given by Darcy's law:
with kth the hydraulic conductivity of the interstitial space and v f is the velocity of solid phase.
The term Q in Eq. (11) denotes the fluid flux entering from the blood vessels into the tumor or the surrounding normal tissue minus the fluid flux exiting through lymphatic vessels, and is expressed as (4):
where Lp, Sv and pv are the hydraulic conductivity, vascular density and vascular pressure, respectively, Lpl, Svl and pl are the corresponding quantities for lymphatic vessels, and pi is the interstitial fluid pressure.
According to the biphasic theory for soft tissues (32), the total stress tensor σtot is the sum of the fluid phase stress tensor σ f = -piI and the solid phase stress tensor σ s . As a result, the stress balance is written as:
where the Cauchy stress tensor of the solid phase σ s is given by (33):
The tumor mechanical behavior was modeled to be incompressible and neo-Hookean with strain energy density given by (34-37):
where μ and k are the shear and bulk modulus of the material, respectively, Je is the determinant of the elastic deformation gradient tensor Fe, II1 = I1Je -2/3 where I1 = trCe is the first invariant of the elastic Cauchy-Green deformation tensor Ce = Fe T Fe, and p is a penalty variable introduced for near incompressible materials. The surrounding normal tissue was assumed to be compressible and neo-Hookean with a Poisson ratio of 0.2.
Functional vascular density
To quantify the functional vascular density, we assume that it is affected by the decrease in the vessel diameter (d/do) owing to the increased number of cancer cells (38) and the elevation of solid stress (39) . Also the functional vascular density depends on the permeability of the tumor vessel wall (40) as hyper-permeable vessels reduce vessel perfusion and functionality.
The functional vascular density will be given from:
where 0 will depend on vessel wall pore size (i.e., permeability) and is the density of endothelial cells which is given below. Vessel wall pore size depends on IFNγ concentration as described below (page 11).
Oxygen Concentration
The rate of change of oxygen in the tumor tissue was taken to depend both on its transport through convection and diffusion, as well as the amount of oxygen consumed by cells, and the amount that enters the tissue from the blood vessels (3, 5), i.e.,
where cox is the oxygen concentration, Dox is the diffusion coefficient of oxygen in the interstitial space, Aox and kox are oxygen uptake parameters, Per is the vascular permeability of oxygen that describes diffusion across the tumor vessel wall and Ciox is the oxygen concentration in the vessels.
The transvascular transport of oxygen was taken to be diffusion dominated given that convection is negligible for oxygen compared to diffusion (41) . Given the uniform alleviation of the interstitial fluid pressure in tumors, pressure gradients within the tissue and across the tumor vessel wall are small (42) and thus, Peclét numbers are expected to be low.
Tumor Vasculature Components
Endothelial cell transport equation
The flux of endothelial cell is given by the equation (43): 
Endothelial cell proliferation is based on VEGF and CXCL12 concentration as well as endothelial (45, 46) .
Pericytes transport equation
Two populations/phenotypes of pericytes are considered: pericytes that are tightly associated with endothelial cells and assumed to be immotile and pericytes that are dissociated from endothelial cells and can be motile. Production rates of both phenotypes depends on PDGF-B concentrations as well as on their own concentrations.
Immotile pericytes transport equation
The pericytes density is given by the equation (47, 48) :
where pc is the total pericytes density (pc=pcim+pcm), p 0 c is the pericyte reference value, pb is the PDGF-B concentration, pcimmax is the carrying capacity of the immotile pericyte density, βpc, λpb, cpb, αp1, αp2, αp3, αp4, μpc are constant positive parameters.
Motile pericytes cells transport equation
The motile pericyte density is given by the equation (47, 48 
where kpc is a chemotactic constant, Dpc is the diffusion coefficient of motile pericytes and μpc2 is a constant positive parameter.
VEGF transport equation

VEGF concentration is determined by diffusion, production from cancer cells under hypoxic
conditions and binding to endothelial cells receptors (43) . VEGF concentration is governed by the equation (43) 
Where � is the dimensionless VEGF concentration calculated with division with a reference value � = 0 and � is the dimensionless oxygen concentration normalized as: � = 0 .
VEGF is assumed to be produced by cancer cells only and its production is enhanced under hypoxic conditions as described by the oxygen tension term Ga (43) .
VEGF becomes unavailable due to binding to endothelial cells VEGF receptors and it can also diffuse in the tumor with a diffusion coefficient VEGF D . λ10, λ11, λ12 and λ13 are positive constants.
Additionally, knockout of CD4 + T cells resulted in overexpression of VEGF (λCD4,Cvegf) and not significant differences in Ang1-Ang2 (21) . The parameter − is a time and dose dependent parameter that describes the effect of anti-VEGF treatment on VEGF levels according to experimental studies (45, 46) .
CXCL12 transport equation
The stromal cell derived factor 1 (SDF1α) is also known as C-X-C motif chemokine 12 (CXCL12).
We suggest in the model that VEGF released by hypoxic cancer cells up-regulates CXCL12 from cancer cells and that CXCL12 is also produced by endothelial cells in a VEGF dependent manner (49) . Therefore, CXCL12 is produced by both cancer cells and endothelial cells and it is also upregulated by hypoxia and VEGF (49) . The transport of CXCL12 is governed by:
where λ10, and λ13 are positive parameters. The dimensionless CXCL12 concentration is given by division with a reference concentration � = 0 .
PDGF-B transport equation
PDGF-B was assumed to be produced by endothelial cells and binds to pericytes (50) . PDGF-B concentration is governed by the equation (51):
where βpd, μpb and γpb are positive parameters, Dpb is the PDGF-B diffusion coefficient.
Ang1 and Ang2 transport equations
Ang1 is assumed to be produced by pericytes and Ang2 by endothelial cells, respectively. Their production is enhanced by hypoxia based on VEGF levels (44) . Angiopoietin 1(Ang1, α1) and angiopoietin 2 (Ang2, α2) are up-regulated by hypoxia and produced by endothelial cells. 1 1
where b1, b2, m1 and m2 are positive constants. The dimensionless Ang1 and Ang2 are given by division with a reference concentration 1 � = 1 1 0 , 2 � = 2 2 0 . The oxygen tension term Ga is the same as used for VEGF and CXCL12. For the simplicity of the equations, we neglect diffusion of Ang1 and Ang2 and binding to specific Tie receptors (52, 53) . (27) where DIFNγ is the diffusion coefficient, IFN production γ λ the production term and deg IFN radation γ λ a degradation term (13, 54) . The production term of IFNγ depends on CD4 + and CD8 + T-cells according to a previous experimental study (21) .
IFNγ transport equation
IFNγ concentration is determined by diffusion, production from CD4 + T-cells and CD8 + T-cells
Furthermore, IFNγ affects the hydraulic permeability of the vessel wall, Lp. In the model, Lp is given as a function of the vessel wall pore size, ro, the fraction of the vessel surface occupied by pores, γ, the viscosity of the fluid in the pores, η, and the thickness of the vessel wall, Lw: showing that elimination of CD4 + and CD8 + T-cells leads to a decrease in IFNγ, which in turn increases vessel wall pore size and vessel permeability by 5-fold (21, 22) .
Solution strategy
The model consists of a spherical tumor domain embedded at the center of a cubic host domain two orders of magnitude larger to avoid any boundary effects on the growth of the tumor; due to symmetry, only one eighth of the system was considered. To this end, Equations (1)-(28) were solved simultaneously using the commercial finite element software COMSOL Multiphysics (COMSOL, Inc., Burlington, MA, USA). Values for the model parameters are provided in Supplementary Table 1 . The boundary conditions for the continuity of the stress and displacement fields, as well as the concentration of the oxygen at the interface between the tumor and the normal tissue, were applied automatically by the software, the remaining boundary conditions are shown in Supplementary Figure S6 . The model consists of 655,458 degrees of freedom (109,341 finite elements) and it takes 23hr 46min 14 sec to simulate tumor growth for 30 days. The COMSOL code is available in (55) . 
Figure S1
Phase diagram for the effect of different doses of anti-VEGF treatment combined with different values of the source term of CD8 + T-cells to model immunotherapy for sequential administration on (A) Stem-like cancer cells and (B) Induced cancer cells. We observe that both low and high doses of anti-VEGF treatment in combination with highest values of immunotherapy are effective but for lower values of immunotherapy only low doses of anti-VEGF treatment decrease number of cells. The values of the model parameters presented in the figure were calculated halfway between the tumor center and periphery.
Figure S2
Effect of different values of the tumor elastic modulus combined with different values of the source term of CD8 + T-cells to model the immunotherapy for sequential administration. (A)-(I) Phase diagrams for the effect of combinatorial treatment of stroma normalization with immunotherapy on functional vascular density, tumor oxygenation, VEGF levels, effector immune cells (NK and CD8 + T-cells) and CD4 + T-cells, M1-like and M2-like TAMs, cancer cell population and tumor volume. Values of model parameters presented in the figure were calculated halfway between the tumor center and periphery.
Figure S3
Phase diagram for the effect of different values of elastic modulus combined with different values of the source term of CD8 + T-cells to model immunotherapy on (A) Stem-like cancer cells and (B) Induced cancer cells. We observe that decrease of Elastic Modulus and alleviation of solid stress enhance the efficacy of immunotherapy. The values of the model parameters presented in the figure were calculated halfway between the tumor center and periphery.
Figure S4
Effect of simultaneous triple therapy of vascular and stroma normalization combined with immunotherpy on tumor volume. Triple therapy is more effective compared to the combinatorial treatment of immunotherapy with vascular normalization or stroma normalization.
Figure S5
Phase digrams of overall tumor volume for the effect of different proliferation and migration (i.e. diffussion) rates of cancer cells in sequential administration of anti-VEGF treatment and immunotherapy. The values of proliferation rates varied from 2.20 to 2.40 day -1 and the values of the diffusion coefficient varied from 1.5×10 -11 to 1.5×10 -13 (m 2 /s). There is no significant difference between different doses of anti-VEGF treatment in overall tumor volume. On the other hand, increasing proliferation and migration rates, the lower values of anti-VEGF treatment are more effective. Furthermore, the differences between anti-VEGF doses are are more sensitive to changes in the proliferation rate of cancer cells than their migration rate.
Figure S6
Computational domain and boundary conditions employed.
